Rate Control in Atrial Fibrillation: The Ejection Fraction That Isn't Quite Reduced
L.H.'s first echocardiogram, ordered after her new atrial fibrillation diagnosis, put her ejection fraction at 43 percent — above the number most guidelines use to rule out one class of rate-control drug, but not clearly normal either.
L.H., a 63-year-old woman, retired last year from three decades running a small hardware store, which she still opens for a few hours most mornings out of habit as much as necessity. She has had well-controlled hypertension for eight years on lisinopril and has never smoked. About six weeks ago she began noticing that restocking shelves left her more winded than it used to, and every so often she felt her heart "trip and flutter" for a few seconds at a time. She assumed it was simply age catching up with her stamina until the fluttering became frequent enough that she mentioned it at a routine visit two weeks ago. An ECG that day showed atrial fibrillation with a ventricular rate of 118 to 124 beats per minute; thyroid studies and electrolytes were unremarkable. Her physician referred her for cardiology evaluation and ordered an echocardiogram, performed a week ago, which showed a left ventricular ejection fraction of 43 percent with mild global hypokinesis (uniformly, mildly weakened contraction rather than a discrete scarred segment), no significant valvular disease, and no prior imaging available for comparison.
That last point is what complicates an otherwise ordinary rate-control decision. An ejection fraction of 43 percent falls just above the threshold at which current guidelines advise against non-dihydropyridine calcium channel blockers altogether, but well below the range where the choice between diltiazem and metoprolol would be a formality. Whether her heart's reduced pumping is a longstanding process only now uncovered, or is itself the result of weeks of an unrecognized rapid rhythm, is not something a single echocardiogram can settle. Her atrial fibrillation has likely been present for at least the six weeks she has felt symptomatic, possibly longer, which is enough time for sustained tachycardia alone to blunt contractile function without any separate structural disease at all. She has no history of chest pain or prior cardiac imaging, and no other new symptoms; today's consultation is her first for a rate-control agent, not a switch from a treatment already tried.
At the first cardiology visit
Her guideline clearance is not ambiguous here. Current recommendations reserve avoiding non-dihydropyridine calcium channel blockers for an ejection fraction at or below 40 percent, and hers is 43. Diltiazem gives reliable, well-tolerated atrioventricular-node blockade, and nothing in her workup has established a structural cardiomyopathy — only a number that happens to sit above the line the guideline itself draws.
I'll concede the guideline's authors weren't picturing a borderline number found the same week as a new arrhythmia. But a guideline that draws a specific line is telling us where the actual evidence runs out, not where caution should start.
The heart-failure guideline draws that same mildly-reduced category for a reason — it says outright that one ejection-fraction measurement, especially early, may not describe where a heart is actually headed. Beta-blockers already carry a real, if weaker, recommendation at this range, with a protective signal that generalizes; calcium channel blockers have never shown one. If we're wrong about which way she's trending, a negative inotrope is the costlier mistake to have made.
Waiting for confirmed structural disease before acting conservatively gets the burden of proof backward. By the time it's confirmed, we've already spent weeks on the wrong side of it.
Both of you are arguing about a number that six weeks of unrecognized tachycardia is fully capable of producing on its own, with no separate heart disease required at all. If that's what's happening here, rate control by either agent should let it recover, and the real decision isn't which drug is superior — it's how much weight to put on one echocardiogram taken while the rhythm causing the problem was still running. Start with the more conservative agent, and let the repeat imaging, not today's debate, be what actually answers the question.
Agreed today: start metoprolol succinate at a low dose, with resting and exertional heart rate guiding titration, and a repeat echocardiogram planned in 8 to 12 weeks now that the arrhythmia itself is being treated.
Not agreed, and left as two live positions rather than a single plan:
The plan holds as written, and the repeat echocardiogram becomes the real answer to how much of today's number belonged to the arrhythmia itself.
The cardiologist would move to diltiazem without hesitation, given the guideline's plain permission at this ejection fraction; the heart failure cardiologist would want the ejection fraction question reopened first, before reaching for it.
Both cardiologists left agreeing on today's prescription and disagreeing about what a stumble next month should mean.